Table 2.
Hazard ratios for CVD among 1‐year cancer survivors compared with age‐, gender‐ and geographically matched cancer‐free controls
| CVD | Follow‐up period in median years | Demographic adjusted HR (95% CI) | Partially adjusted HR (95% CI) | Fully adjusted HR (95% CI) | |
|---|---|---|---|---|---|
| Breast cancer | |||||
| Years 0‐7 | |||||
| Survivors | 358 (7) | 3 (0‐7) | 0.99 (0.86‐1.15) | 0.95 (0.82‐1.10) | 0.95 (0.82‐1.10) |
| Controls | 343 (6) | 3 (0‐7) | |||
| Years 8‐13 | |||||
| Survivors | 41 (3) | 9 (8‐13) | 1.43 (0.96‐2.12) | 1.38 (0.93‐2.05) | 1.38 (0.93‐2.05) |
| Controls | 29 (3) | 9 (8‐13) | |||
| Prostate cancer | |||||
| Survivors | 149 (3) | 3 (1‐13) | 1.17 (1.01‐1.35)a | 1.12 (0.96‐1.30) | 1.12 (0.96‐1.29) |
| Controls | 187 (4)a | 2 (0‐13) | |||
| Non‐Hodgkin | |||||
| Years 0‐3 | |||||
| Survivors | 79 (8) | 1 (0‐3) | 1.04 (0.77‐1.41) | 1.00 (0.74‐1.35) | 1.01 (0.75‐1.38) |
| Controls | 74 (7) | 1 (0‐3) | |||
| Years 4‐13 | |||||
| Survivors | 34 (6) | 6 (4‐13) | 1.50 (0.94‐2.38) | 1.46 (0.92‐2.32) | 1.46 (0.92‐2.32) |
| Controls | 18 (4) | 6 (4‐13) | |||
| Lung and trachea cancer | |||||
| Survivors | 119 (5) | 0 (0‐13) | 1.48 (1.10‐1.97)a | 1.45 (1.07‐1.91)a | 1.41 (1.06‐1.89)a |
| Controls | 75 (3)a | 0 (0‐13) | |||
| BCC cancer | |||||
| Survivors | 898 (7) | 3 (0‐13) | 1.08 (0.98‐1.19) | 1.04 (0.95‐1.15) | NA |
| Controls | 758 (6)a | 3 (0‐13) | |||
| Colorectal cancer | |||||
| Survivors | 290 (7) | 2 (0‐8) | 1.18 (1.00‐1.41) | 1.13 (0.95‐1.34) | 1.13 (0.95‐1.34) |
| Controls | 234 (5)a | 2 (0‐8) | |||
BCC, basal cell carcinoma; NA, not applicable.
a
P < 0.05. Demographic adjusted model: adjusted for demographics (ie, age and gender). Partially adjusted model: adjusted for demographics and traditional cardiovascular risk factors (ie, hypertension, hypercholesterolemia, and diabetes mellitus present in the 12 months prior to cancer diagnosis or corresponding date for the cancer‐free controls). Fully adjusted model: adjusted for demographics, traditional cardiovascular risk factors and cancer treatment (ie, chemotherapy, radiation and additionally for hormonal treatment for breast and prostate cancer).